Orbital radiotherapy for Graves' ophthalmopathy: Useful or useless? Safe or dangerous?

被引:20
作者
Bartalena, L
Marcocci, C
Gorman, CA
Wiersinga, WM
Pinchera, A
机构
[1] Univ Insubria, Dept Endocrinol, Varese, Italy
[2] Univ Pisa, Dept Endocrinol, Pisa, Italy
[3] Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA
[4] Univ Amsterdam, Acad Med Ctr, Dept Endocrinol & Metab, NL-1105 AZ Amsterdam, Netherlands
关键词
Graves' ophthalmopathy; orbital radiotherapy; side effects; glucocorticoids; cataract; radiation retinopathy;
D O I
10.1007/BF03345116
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment of Graves' ophthalmopathy does not always provide favorable results. After several decades of efforts, glucocorticoids, orbital radiotherapy (OR) and surgery (orbital decompression) remain the milestones in the management of this disease. OR produce favorable results in about 55-60% of patients. Its effectiveness is increased by the association with systemic glucocorticoids. Recent studies have cast some doubts on its real effectiveness and this is discussed by participants in this Forum. Selection of patients is particularly important to assess treatment outcome, because OR is unlikely to provide beneficial effects in patients with longstanding and inactive eye disease. OR is a safe procedure, with very limited side-effects. It should be used in patients older than 35 years of age. It is recommended that a large, multi-center, prospective, randomized and controlled study with well defined inclusion criteria be carried out to draw sound conclusions on the role of OR in the management of Graves' ophthalmopathy. ((C))2003, Editrice Kurtis.
引用
收藏
页码:5 / 16
页数:12
相关论文
共 35 条
[1]   Management of Graves' ophthalmopathy: Reality and perspectives [J].
Bartalena, L ;
Pinchera, A ;
Marcocci, C .
ENDOCRINE REVIEWS, 2000, 21 (02) :168-199
[2]   ORBITAL COBALT IRRADIATION COMBINED WITH SYSTEMIC CORTICOSTEROIDS FOR GRAVES OPHTHALMOPATHY - COMPARISON WITH SYSTEMIC CORTICOSTEROIDS ALONE [J].
BARTALENA, L ;
MARCOCCI, C ;
CHIOVATO, L ;
LADDAGA, M ;
LEPRI, G ;
ANDREANI, D ;
CAVALLACCI, G ;
BASCHIERI, L ;
PINCHERA, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1983, 56 (06) :1139-1144
[3]   Smoking and Graves' disease [J].
Bartalena, L .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (05) :402-402
[4]   Management of thyroid eye disease [J].
Bartalena, L ;
Marcocci, C ;
Tanda, ML ;
Pinchera, A .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (Suppl 2) :S458-S465
[5]   Orbital radiotherapy for Graves' ophthalmopathy [J].
Bartalena, L ;
Marcocci, C ;
Tanda, ML ;
Rocchi, R ;
Mazzi, B ;
Barbesino, G ;
Pinchera, A .
THYROID, 2002, 12 (03) :245-250
[6]  
Bartalena Luigi, 2002, Hormones (Athens), V1, P76
[7]   Long-term follow-up of Graves ophthalmopathy in an incidence cohort [J].
Bartley, GB ;
Fatourechi, V ;
Kadrmas, EF ;
Jacobsen, SJ ;
Ilstrup, DM ;
Garrity, JA ;
Gorman, CA .
OPHTHALMOLOGY, 1996, 103 (06) :958-962
[8]   Place of radiotherapy in the treatment of Graves' orbitopathy [J].
Beckendorf, V ;
Maalouf, T ;
George, JL ;
Bey, P ;
Leclere, J ;
Luporsi, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (04) :805-815
[9]   Probable risk of tumor induction after retro-orbital irradiation for Graves' ophthalmopathy [J].
Blank, LECM ;
Barendsen, GW ;
Prummel, MF ;
Stalpers, L ;
Wiersinga, W ;
Koornneef, L .
RADIOTHERAPY AND ONCOLOGY, 1996, 40 (02) :187-188
[10]   Assessment of a carcinogenic risk for treatment of Graves' ophthalmopathy in dependence on age and irradiation geometry [J].
Broerse, JJ ;
Snijders-Keilholz, A ;
Jansen, JTM ;
Zoetelief, J ;
Klein, C ;
Seegenschmiedt, MH .
RADIOTHERAPY AND ONCOLOGY, 1999, 53 (03) :205-208